Clinical Epidemiology
Volume 5, 2013 - Issue
Open access
95
Views
29
CrossRef citations to date
0
Altmetric
Review
The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®)
Charlotte Höybye1 Department of Molecular Medicine and Surgery, Karolinska Institute and Department of Endocrinology, Metabolism and Diabetes, Stockholm, SwedenCorrespondence[email protected]
, Lars Sävendahl2 Department of Women’s and Children’s Health, Karolinska Institute and Division of Pediatrics, Karolinska University Hospital, Stockholm, Sweden
, Henrik Thybo Christesen3 Hans Christian Andersen Children’s Hospital, Odense University Hospital, Odense, Denmark
, Peter Lee4 Department of Pediatrics, Penn State College of Medicine, Hershey, PA, USA
, Birgitte Tønnes Pedersen5 Global Development, Novo Nordisk A/S, Søborg, Denmark
, Michael Schlumpf6 Global Medical Affairs Biopharm, Novo Nordisk Health Care AG, Zurich, Switzerland
, John Germak7 Clinical Development and Medical Affairs, Novo Nordisk Inc, Princeton, NJ, USA
& Judith Ross8 Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA, USA
show all
Pages 119-127
|
Published online: 26 Apr 2013
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.